


De Gruyter Brill

SPECIAL ISSUE AT OPEN MEDICINE

DIABETES AND CANCER IN THE AGE OF MULTIMORBIDITY: BIOLOGICAL INTERACTIONS, THERAPEUTIC CHALLENGES, AND INTEGRATED CARE PATHWAYS

GUEST EDITORS

Prof Dr Panoutsopoulos Georgios University of the Peloponnese, Greece

Prof. Subrata Mallick Siksha'O'Anusandhan, (Deemed to be University), Kalinganagar, Bhubaneswar-751003, Odisha, India

OVERVIEW

The coexistence of diabetes mellitus and cancer is becoming increasingly common due to population ageing, rising obesity prevalence, and improvements in survival from chronic diseases. Although epidemiological studies have identified associations between type 2 diabetes and several cancer types, the underlying mechanisms, clinical implications, and therapeutic consequences remain incompletely understood.

This Special Issue aims to provide a focused examination of the biological, pharmacological, and clinical intersections between diabetes and cancer within the broader framework of multimorbidity. Rather than emphasizing generalized associations, the issue will concentrate on specific scientific and clinical questions related to metabolic dysfunction, chronic inflammation, insulin resistance, treatment-related complications, and integrated patient management.

Particular attention will be given to the bidirectional relationship between diabetes and selected cancers, including hepatocellular, pancreatic, colorectal, breast, and endometrial malignancies. The issue will also explore the impact of antidiabetic therapies on cancer risk and outcomes, cancer treatment–induced metabolic disturbances, and potential pharmacological interactions that influence patient safety and therapeutic effectiveness.

By bringing together epidemiological, mechanistic, translational, and clinical research, this Special Issue seeks to advance evidence-based understanding and improve care pathways for patients affected by both conditions.

OBJECTIVES

This Special Issue aims to:

•Clarify the biological mechanisms linking diabetes and specific cancer types.
• Evaluate the role of metabolic dysfunction, insulin resistance, hyperglycaemia, obesity, and chronic inflammation in cancer development and progression.
• Investigate the effects of antidiabetic medications on cancer incidence, prognosis, and survival.
• Examine metabolic complications arising from cancer therapies and their impact on diabetes management.
• Identify clinically relevant pharmacological interactions between antidiabetic agents and anticancer treatments.
• Explore integrated multidisciplinary care models for patients with diabetes and cancer.
• Highlight opportunities and limitations of precision medicine, multi-omics approaches, and artificial intelligence in risk stratification and treatment optimisation.

THEMATIC SCOPE

The Special Issue will particularly welcome manuscripts addressing:

1. Biological Mechanisms and Disease Pathogenesis
2. Epidemiology and Risk Assessment
3. Pharmacological Interactions and Therapeutic Implications
4. Clinical Management and Integrated Care
5. Emerging Technologies

The Special Issue particularly seeks:

• Original clinical and translational research studies

• Prospective cohort studies and registry analyses

• Mechanistic and experimental investigations

• Systematic reviews and meta-analyses

• Evidence-based narrative reviews

• Clinical practice perspectives

• Health services and implementation research

Priority will be given to submissions that provide clear clinical relevance, methodological rigor, reproducible analyses, and direct implications for patient care.

CONCLUSION

This special issue is precisely aligned, and high impact that directly addresses a major gap in current research and practice in the field of diabetes and cancer. By analyzing diabetes and cancer within the clinically relevant context of multimorbidity offers a compelling and credible contribution to the field. It offers a timely and balanced platform to advance understanding while avoiding overstatement of mechanistic links.

IMPORTANT DATES & HOW TO SUBMIT

To Submit a paper please use our system: https://www.editorialmanager.com/openmed/ As a Section Category please choose: SI Diabetes and Cancer. Submissions to this special issue can expect 30% discount for publication. Deadline for manuscripts submission: 30 June 2027.